Top 10 Oncology Stocks to Buy Now

Page 9 of 9

1. Merck & Co., Inc. (NYSE:MRK

Number of Hedge Fund Holders: 92

Merck & Co., Inc. (NYSE:MRK) tops our list for being one of the best cancer stocks.

TheFly reported on January 8 that Wolfe Research analyst Alexandria Hammond upgraded MRK to Outperform from Peer Perform with a $135 price target. The firm described the five-year revenue outlook as “attractive” and stated that the stock is “poised for a breakout” after accretive M&A and ahead of a catalyst-rich era after integrating MRK’s late-stage pipeline, possible label expansions, and prescriber feedback into its models.

Separately, on January 9, reports emerged that MRK is in active talks to acquire Revolution Medicines for approximately $30 billion.

Merck & Co., Inc. (NYSE:MRK) is a leading oncology company driven by its blockbuster immunotherapy Keytruda, with a diversified cancer portfolio spanning immuno-oncology, targeted therapies, and combination regimens, supported by an expanding clinical pipeline and strategic acquisitions to sustain long-term growth.

While we acknowledge the potential of MRK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRK and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.

Page 9 of 9